New OrleansJune 8, 2026 /PRNewswire/ — Hangzhou Sciwind Biosciences Co., Ltd. (“Sciwind Biosciences”), a commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, today announced that key data from the head-to-head study (SLIMMER-UP-SWITCH) of Enoglutide, the world’s first approved cAMP-biased GLP-1 receptor agonist, versus Semaglutide, were officially presented as a “Late Breaking” abstract at the 2026 American Diabetes Association (ADA) Scientific Sessions. Interim analysis data from the study showed that Enoglutide demonstrated significantly superior weight loss efficacy compared to Semaglutide, with a 35% greater reduction in body weight at 20 weeks, a 20% greater reduction in waist circumference, and nearly twice the proportion of patients achieving ≥10% weight loss[1].
Professor Ji Linong, Director of the Department of Endocrinology at Peking University People’s Hospital, believes that this study provides the first direct clinical evidence validating the clinical advantages of the innovative mechanism of cAMP-biased GLP-1 receptor agonists. By optimizing GLP-1 receptor signaling, it can achieve superior clinical benefits compared to traditional GLP-1 receptor agonists, offering high-quality evidence-based medical evidence for the field of weight management.
Clear 20-Week Weight Loss Advantage: Average Weight Loss 35% Greater than Semaglutide, Nearly 2x Rate of ≥10% Weight Loss Response
This study enrolled 163 adult obese patients (BMI ≥30 kg/m²) across 17 research centers in China. Participants were randomized 1:1 to receive equivalent doses (2.4 mg) of Enoglutide or Semaglutide via weekly subcutaneous injections1.
Study data showed: At 20 weeks of treatment, the average weight loss from baseline was 12.8% in the Enoglutide group and 9.5% in the Semaglutide group (P<0.0001). The proportion of participants achieving ≥5% weight loss was 99% in the Enoglutide group and 86% in the Semaglutide group (P<0.01). The proportion achieving ≥10% weight loss was 74% in the Enoglutide group and 40% in the Semaglutide group (P<0.001).
Impressive Circumference Benefits: Waist Circumference Reduction 20% Greater than Semaglutide
In addition to potent weight loss, the Enoglutide group also showed significant advantages in body circumference improvements. Study data showed that at 20 weeks of treatment, the average waist circumference reduction from baseline was 10.5 cm in the Enoglutide group and 8.7 cm in the Semaglutide group (P<0.05), representing a 20% greater reduction for Enoglutide. Improvements in multiple circumference measures, including arm circumference and neck circumference, were all superior to Semaglutide1.
Professor Ji Linong noted: Central obesity, characterized by abdominal fat accumulation, not only affects body shape but is also a significant risk factor for type 2 diabetes, metabolic syndrome, and cardiovascular disease. While effectively reducing body weight, Enoglutide can significantly improve central obesity and localized fat accumulation, thereby reducing the risk of related metabolic diseases in addition to optimizing body shape.
Translation of Nobel Prize-Winning Research: Biased Mechanism Achieves Both Efficacy and Safety
Traditional GLP-1 receptor agonists often employ a “full-pathway activation” mode. While activating weight loss signaling pathways, they also tend to activate pathways associated with gastrointestinal adverse reactions and receptor desensitization, making it difficult to achieve both potent weight loss and good tolerability.
Building on Nobel Prize-winning research findings3, Enoglutide effectively overcomes the industry challenge of balancing efficacy and tolerability in traditional weight loss treatments by optimizing GLP-1 receptor signaling. Its safety profile was also validated in this head-to-head study data. Consistent with previous SLIMMER study results, Enoglutide demonstrated a favorable gastrointestinal safety profile1-2.
Dr. Pan Hai, Founder and CEO of Sciwind Biosciences, stated: “We are honored to present this significant achievement at the top global metabolic conference, the ADA Annual Meeting. Better weight loss treatment options may not necessarily come from simply stacking targets, but from precise regulation of key biological mechanisms. This head-to-head study of Enoglutide provides direct clinical evidence for this, marking an important milestone in the transition of biased mechanisms from cutting-edge science to clinical application. From Nobel Prize-level basic research to clinical products benefiting patients, we remain committed to the original intent of scientific translation, ensuring more cutting-edge scientific achievements truly translate into health benefits for patients.”
Jean-Christophe Pointeau, Senior Vice President of Pfizer and President of Pfizer China, stated: “We are delighted to see the impressive clinical data from this head-to-head study of Enoglutide. This data demonstrates the breakthrough potential of the new generation of biased GLP-1 in weight management and metabolic treatment. As the leader in the commercialization process of Enoglutide, Pfizer will leverage its deep experience and resource advantages accumulated in the Chinese market to accelerate the launch of this innovative therapy, ensuring cutting-edge science truly benefits every Chinese patient in need.”
About the SLIMMER-UP-SWITCH Head-to-Head Study1
SLIMMER-UP-SWITCH is a multicenter, randomized, open-label Phase II clinical trial. It enrolled 163 obese adult patients (BMI ≥30 kg/m²) across 17 research centers in China. Participants were randomized 1:1 to receive weekly subcutaneous injections of Enoglutide or Semaglutide for a 60-week treatment period, with a pre-specified interim analysis conducted at week 20. The interim analysis data from this study were selected for a Late Breaking abstract presentation (poster) at the 2026 American Diabetes Association (ADA) Scientific Sessions.
About the SLIMMER Study2
The SLIMMER study is a large-scale Phase III clinical trial that enrolled 664 Chinese adult overweight or obese subjects. In the SLIMMER study, Enoglutide demonstrated clinically meaningful efficacy. After 48 weeks of treatment, subjects in the highest dose group (2.4 mg) achieved an average weight loss of 15.4%, with 92.8% of subjects achieving ≥5% weight loss. The study also observed significant reductions in waist circumference (average decrease of 12.8 cm), a 53.1% average reduction in liver fat content in subjects with baseline fatty liver disease, and significant improvements in multiple metabolic parameters including blood pressure, lipids, and blood glucose. Additionally, uric acid levels decreased by an average of 54.3 μmol/L. In the study, the discontinuation rate due to adverse events was 2%, and the discontinuation rate due to gastrointestinal adverse events was 0.6%.
About Sciwind Biosciences
Sciwind Biosciences is a commercial-stage biopharmaceutical company dedicated to addressing the urgent medical needs in the field of weight management. The company has established a robust product pipeline anchored by its core asset (Enoglutide injection, etc.). Sciwind Biosciences possesses a biased agonist discovery platform, an oral peptide delivery platform, and a half-life extension platform. Based on these three core technology platforms, the company has identified a series of drug candidates, building a comprehensive product pipeline covering GLP-1 and its synergistic mechanisms, providing sustainable and high-quality treatment options, including injectable and oral formulations, for patients with metabolic diseases.
For more information, please visit the Sciwind Biosciences website: www.sciwind.com.cn